Overview
Opioid-induced bowel dysfunction (OIBD) is refers to a
collection of primarily gastrointestinal motility disorders induced by opioids.
OIBD is commonly associated with the chronic use of opioid analgesics. Symptoms
include constipation, anorexia, nausea and vomiting, gastro-esophageal reflux,
delayed digestion, abdominal pain, flatulence, bloating, hard stool, straining
during bowel movement and incomplete evacuation. Treatment includes laxatives,
stool softeners, osmotic agents and opioid antagonist.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1555349-opioid-induced-bowel-dysfunction-obd-or-oibd-pipeline-review-h1-2017
Report
Highlights
The Pharmaceutical and Healthcare latest pipeline guide
Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, H1 2017,
provides comprehensive information on the therapeutics under development for
Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology), complete with
analysis by stage of development, drug target, mechanism of action (MoA), route
of administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and development
history and latest news and press releases.
The Opioid-Induced Bowel Dysfunction (OBD or OIBD)
(Toxicology) pipeline guide also reviews of key players involved in therapeutic
development for Opioid-Induced Bowel Dysfunction (OBD or OIBD) and features dormant
and discontinued projects. Opioid-Induced Bowel Dysfunction (OBD or OIBD)
(Toxicology) pipeline guide helps in identifying and tracking emerging players
in the market and their portfolios, enhances decision making capabilities and
helps to create effective counter strategies to gain competitive advantage.
Additionally, various dynamic tracking processes ensure that the most recent
developments are captured on a real time basis.
Major Scope of the report:
- The pipeline guide provides a snapshot of the global
therapeutic landscape of Opioid-Induced Bowel Dysfunction (OBD or OIBD)
(Toxicology).
- The pipeline guide reviews pipeline therapeutics for Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide reviews pipeline therapeutics for Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) therapeutics and enlists all their major and minor projects.
Table of Contents
List of Figures
Introduction
Global Markets Direct Report Coverage
Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Overview
Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Companies Involved in Therapeutics Development
ChironWells GmbH
RaQualia Pharma Inc
Vitality Biopharma Inc
Introduction
Global Markets Direct Report Coverage
Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Overview
Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Companies Involved in Therapeutics Development
ChironWells GmbH
RaQualia Pharma Inc
Vitality Biopharma Inc
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1555349-opioid-induced-bowel-dysfunction-obd-or-oibd-pipeline-review-h1-2017
About Us
Wise Guy
Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium
progressive statistical surveying, market research reports, analysis &
forecast data for industries and governments around the globe. Wise Guy Reports
understand how essential statistical surveying information is for your
organization or association. Therefore, we have associated with the top
publishers and research firms all specialized in specific domains, ensuring you
will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner
Relations & Marketing Manager
Ph:
+1-646-845-9349 (US)
Ph: +44 208
133 9349 (UK)
No comments:
Post a Comment